Abstract. Inhibitor of dsRNA-dependent protein kinase (PKRI) and medroxyprogesterone acetate (MPA) improve cancer cachexia via different mechanisms. We aimed to compare these two drugs, alone or in combination, in cancer cachexia in mice. Forty male BABL/c mice aged 6-8 weeks were randomly divided into PKRI, MPA, PKRI+MPA, placebo, and healthy control groups. The first 4 groups were injected with colon-26 adenocarcinoma and fed for 12 days and then treated with PKRI and MPA alone or in combination for 7 days. Body weight, tumor volume, wet weight of gastrocnemius muscle, serum levels of nutritional markers and cytokines were measured. The tumor growth (volume and weight) of mice treated with PKRI, MPA alone or PKRI+MPA was slower than that of placebo group. Wet weight of gastrocnemius muscle was significantly higher in PKRI and PKRI+MPA-treated than in placebo animals (P<0.01). All tumor-bearing mice had a significantly lower level of blood glucose, higher level of serum triglyceride and lower level of serum albumin compared with healthy control (P<0.001). However, PKRI, MPA and PKRI+MPA groups had a significant higher level of blood glucose and lower level of serum triglyceride compared with placebo group (P<0.001). All tumor bearing mice had a significant higher level of serum TNF-α, IL-1 and IL-6 compared with healthy control (P<0.001). Serum level of TNF-α and IL-6 was significantly lower in PKRI and PKRI+MPA-treated than in placebo animals (P<0.01). PKRI alone and combination therapy with PKRI and MPA reduce tumor growth and may alleviate cachexia.
Introduction
Cancer cachexia (CC) is a complication of end stage cancer, characterized by progressive loss of body weight and metabolic disorders. It leads to compromised quality of life and shortened survival time. The pathogenesis of cancer cachexia is multiple, and the potential mechanisms have been extensively studied. But there is still little known about clinical treatment of this condition (1-3). Many trials have been performed in the search for a treatment for cachexia, but most therapies have not fulfilled expectations (4) (5) (6) . Therefore, continuing to probe the pathogenesis and therapies of cancer cachexia holds clinical significance.
One metabolic abnormality in cancer cachexia is a loss of skeletal muscle protein, due to a depression in protein synthesis (7) combined with an increase in protein degradation (8) , both events initiated by inflammatory mediators and by cachectic factors released from tumor tissue (9) . Recent research (10) has shown activation of dsRNA-dependent protein kinase (PKR), a serine/threonine kinase, responsible for the linking two cachectic signaling molecules, proteolysis-inducing factor (PIF) and angiotensin II (Ang II), to decreased synthesis and increased degradation of skeletal muscle protein.
In response to catabolic stimuli such as PIF and Ang II, PKR binds its activator, dsRNA (11) and is activated through autophosphorylation. Active PKR phosphorylates α-subunit of the translation factor, eukaryotic initiation factor 2 (eIF2-α) and the phosphorylated eIF2-α acts as a competitive inhibitor to prevent translation initiation and thus inhibit synthesis of muscle protein (12) . PKR also activates the transcription factor, nuclear factor-κB (NF-κB), through phosphorylation and removal of the inhibitor of κB (13) thus, increasing protein degradation by inducing the ubiquitin-proteasome pathway.
The inhibitor of dsRNA-dependent protein kinase (PKRI) is an imidazolo-oxindole compound that inhibits PKR autophosphorylation and activation (14) . PKRI has been shown to attenuate muscle atrophy in the MAC16 murine cachexia model through increasing protein synthesis and decreasing protein degradation (15) . These data suggest that inhibitors of PKR activation may be useful in the treatment of cancer cachexia.
A second metabolic abnormality in cancer cachexia is a loss of fat stores that is often accompanied by loss of appe-tite. Medroxyprogesterone acetate (MPA, chemical name 17-α-acetoxy-6α-methylprogesterone) (16) currently is the only approved drug in Europe for the clinical treatment of cancer cachexia syndrome. In placebo-controlled trials, MPA led to increased appetite and weight gain and improved quality-oflife, although the weight gain was due to increased body fat since muscle protein was not significantly affected (17) .
Reports from previous preclinical and clinical studies suggest that suppression of secretion of some cytokines (such as TNF-α and IL-6) may, at least in part, cause the anticachectic effect of MPA (18) (19) (20) . There is also evidence that MPA may stimulate appetite through a CNS action involving neuropeptide Y (21) .
Because PKRI mainly improves protein metabolism and MPA mainly improves appetite and increases body fat, there may be an advantage to combination therapy with these two drugs. The present study was performed to evaluate the effect of PKRI and MPA, alone and in combination, on cancer cachexia mice and to investigate potential mechanisms for their effects. Animals. BALB/c male mice (6-8-week old, 20-24 g body weight) were purchased from the Animal Center of the Chinese Academy of Sciences (Shanghai, China; SPF certificate numbers: SCXK (Hu)2007-0005). Specific pathogen-free housing and care was provided by the Animal Center of Fujian Medical University, which provided free access to standard laboratory chow and tap water in a temperature-controlled room (22±1˚C) on a 12-h light-dark cycle. The experimental protocol was approved by the Animal Use Committee at our institution.
Materials amd methods

Materials
Forty healthy mice were randomly divided into 5 groups: (A) PKRI group, (B) MPA group, (C) PKRI+MPA group, (D) placebo group and (E) healthy control group (n=8 in each group). Mice in the first four groups were injected s.c. in the anterior subaxilla with a homogenate of 50 mg (2-3 mm 3 ) of minced solid murine C-26 adenocarcinoma in 0.1 ml 0.9% NaCl (Day 1), as previously described (22) . Day 12 was chosen for establishment of cachexia since by Day 12, the non-tumor weights of the tumor-bearing mice are significantly different from those of healthy mice, together with apparent cachexic signs and symptoms (poor physical activity, asthenia, piloerection, shedding, and non-glossy fur) (15, 23) .
On Day 12, different interventions were implemented in all groups. Mice in PKRI group were administered with 100 µl PKRI (5 mg/kg) s.c. and 1.0 ml 5% Tween-80 intragastrically while mice in MPA group was administered with 100 µl 10% DMSO s.c. and 1.0 ml MPA (120 mg/kg), intragastrically. In addition, mice in PKRI+MPA group were administered with 100 µl PKRI (5 mg/kg) s.c. and 1.0 ml MPA (120 mg/kg) intragastrically while mice in placebo group and control group received 100 µl 10% DMSO s.c. and 1.0 ml 5% Tween-80, intragastrically. All the mice were administered once a day for seven days.
Physical activity, fur condition, body weight, food intake and tumor inoculation site for all mice were monitored daily from Day 1. Tumor volume (V, cm 3 ) was estimated from Day 5 onward using the formula V = ab 2 /2, where 'a' is length and 'b' is width. When the treatments were finished (Day 19), blood samples from anesthetized mice were collected from orbital veins by enucleation of the eyeball and subjected to centrifugation at 4000 rpm for 10 min. The resulting serum was collected and stored at -20˚C for further study. Finally all mice were sacrificed by cervical dislocation. The tumors in the tumor-bearing mice and the left rear gastrocnemius muscles in all laboratory mice were then quickly dissected out and precisely weighed.
Biochemistry. Blood glucose (Glu), serum triglyceride (Tg), serum albumin (Alb) and total protein (TP), used as biochemical indicators of nutritional status, were measured by routine analysis. (Olympus AU2700 Biochemistry Analyzer, Japan).
Enzyme-linked immunosorbent assay (ELISA). Serum cytokines such as TNF-α, IL-1 and IL-6 are closely linked with cachexia. The serum levels of these three cytokines were measured by ELISA as instructed by the manufacturers. Statistical analysis. Means and standard deviations were calculated for each group. Tumor volume and body weight measured over study period were analyzed at the end of Day 19. Comparisons were performed with ANOVA with post-hoc comparison adjusted by the Bonferroni method. Data were analyzed with SAS 9.0 (SAS Institute Inc., Cary, NC), and a P-value <0.05 was considered statistically significant.
Results
Tumor volume. The tumors of tumor-bearing mice could be touched from Day 5 on. The growth of the tumor accelerated from Day 8 on and the increase in tumor volume of mice treated with PKRI, MPA alone or PKRI+MPA was slower than that of mice treated with placebo (Fig. 1A) . On Day 19, mice treated with PKRI and PKRI+MPA had a significantly smaller tumor volume (final tumor volume) than mice treated with placebo (Fig. 1B, P=0 .013 and P=0.008, respectively).
Body weight. The body weight of mice in the five groups had no significant differences between them at the beginning and for several days. The body weight of tumor-bearing mice began to decline on Day 11, and dropped to the lowest levels on Day 16, and then had a slight increase because of the tumor growth ( Fig. 2A) . There was no difference in body weight between the groups at the beginning of the experiment (Fig. 2B) . At the end of experiment, there was a slightly but significantly lower body weight in MPA and PKRI+MPA groups comparing with the healthy control group (Fig. 2C) .
Tumor weight and tumor-free body weight. On Day 19, the tumor weights of groups PKRI, MPA and PKRI+MPA were significantly different from that of the placebo group (Fig. 3A) , P= 0.039, P= 0.06, <0.01, respectively). A significantly lower tumor-free body weight was found in all treatment groups compared to that of the healthy control group (Fig. 3B) .
Muscle weight. Skeletal muscle (gastrocnemius wet weight) weight was significantly lower in all tumor-bearing groups than in the healthy control group (P<0.01). Skeletal muscle weight was significantly higher in PKRI and PKRI+MPA-treated than in placebo animals (P<0.01), but showed no significant increase over body weight of placebo-treated animals in animals treated with MPA alone (Fig. 4) . In fact, skeletal muscle weight was significantly higher also in PKRI and PKRI+MPA-treated than in animals treated with MPA alone (P<0.01). Metabolic indicators. All tumor-bearing mice had a significantly lower level of blood Glu (Fig. 5A) and a significant higher level of serum Tg (Fig. 5B ) compared with healthy control animals (all, P<0.001). Furthermore, the PKRI, MPA and PKRI+MPA groups had a significantly higher level of blood glucose (Glu) and a significantly lower level of serum triglyceride (TG) compared with placebo group (all, P<0.001). Serum total protein (STP) was significantly lower in the placebo group than in healthy controls but it returned to normal level in all treatment groups (Fig. 5C ). Group PKRI, MPA, PKRI+MPA and placebo groups had a significantly lower level of serum albumin (Alb) compared with healthy control (all, P<0.001) (Fig. 5D) .
Serum cytokines. For the serum level of TNF-α, PKRI, MPA, PKRI+MPA and placebo groups were significantly higher than healthy control (Fig. 6A) . Serum level of TNF-α was significantly lower in PKRI and PKRI+MPA-treated than in placebo animals (P<0.01), but showed no significant decrease in animals treated with MPA alone (Fig. 6A) . In fact, the serum level of TNF-α was significantly lower also in PKRI and PKRI+MPA-treated than in animals treated with MPA alone (P<0.01). All tumor bearing mice had a significantly higher level of serum IL-1 compared with healthy controls (all, P<0.001) (Fig. 6B) . All tumor bearing mice had a significantly higher level of serum IL-6 compared with healthy control (all, P<0.001) (Fig. 6C) . The serum level of IL-6 was significantly lower in PKRI and PKRI+MPA-treated than in placebo animals (P<0.01), but showed no significant decrease in animals treated with MPA alone (Fig. 6C) . In fact, the serum level of IL-6 was significantly lower also in PKRI and PKRI+MPA-treated than in animals treated with MPA alone (P<0.01).
Discussion
In this study, we compared the effects of treatment with PKRI, an inhibitor of dsRNA-inducible protein kinase, and MPA, a progesterone analog, alone or in combination, in a mouse model of cancer cachexia. Cancer cachexia is a complex condition including reduced food intake, muscle wasting, anemia, and changes in immune function. The muscle wasting seen in cachexia is due to reduced protein synthesis due to increased phosphorylation by dsRNA-dependent protein kinase of the initiation factor eFI2 and subsequent decreased binding of methionyl tRNA to the 40S ribosomal subunit, and to increased protein degradation through the ubiquitin-proteosome pathway. Proteolysis-inducing factor (PIF), a glycoprotein secreted by tumors, and substances such as glucocorticoids, angiotensin II, and TNFα can all cause muscle wasting (24) . Several new agents, including androgen-receptor modulators and antagonists of inflammatory cytokines that promote muscle breakdown, are currently in clinical development for cancer cachexia treatment (6, 24, 25) .
In our study, tumor growth (both tumor volume and tumor weight) of mice treated with PKRI, MPA, and PKRI+PKA was slower than that of mice treated with placebo. On Day 19, the tumor weight of PKRI, MPA, and PKRI+MPA groups was significantly lower than that of the placebo group. Skeletal muscle weight (gastrocnemius wet weight) was significantly lower in all tumor-bearing groups than in the healthy control group (P<0.01). However, it was significantly higher in PKRI and PKRI+MPA-treated than in placebo-treated animals (P<0.01).
Our finding was supported by previous reports. The administration of MPA, in placebo-controlled trials, has been reported to improve body weight, anorexia, and quality of life, but to improve body weight only by increasing fat and not by increasing muscle protein (17) . However, it has been suggested that the combination of MPA and other anti-cachectic treatments might have therapeutic value (17) . PKRI has been shown to decrease both tumor growth and skeletal muscle atrophy in a mouse model of MAC16 cancer cachexia (26) . In vitro in MAC16 tumor cells, PKRI inhibited cell proliferation at a concentration of 200 nM, a concentration that also caused maximal inhibition of PKR and eIF2 phosphorylation (26) . In another in vitro study, PKRI completely blocked both the Ang II and PIF-induced increase in proteasome expression and activity and the accompanying increase in protein degradation, presumably by preventing PIF and Ang II-caused nuclear migration of the transcription factor NF-κB (10) .
All tumor-bearing mice had a significantly higher levels of serum triglyceride compared with healthy controls. Cancer cachexia is characterized by the uncontrolled loss of adipose and muscle mass (27) . Compared with non-tumor-bearing animals, the rate of triglyceride production increased almost threefold in animals bearing the MAC13 tumor (28) . In our study, the PKRI, MPA, and PKRI+MPA groups had a significantly lower level of triglyceride than the placebo group. The inhibition of lipolysis through genetic ablation of adipose triglyceride lipase or hormone-sensitive lipase significantly ameliorates certain features of cancer cachexia (27) .
All tumor-bearing mice had a significantly lower level of blood glucose compared with healthy controls. In our study, the PKRI, MPA, and PKRI+MPA groups had a significantly higher level of blood glucose than the placebo group. The mechanism of decrease in the level of glucose in tumor-bearing mice is unknown. It might result from reducing appetite (reduced food intake). Whether the higher level of blood glucose in PKRI, MPA, and PKRI+MPA groups associated with increase in appetite remained to be studied.
All tumor-bearing mice had significantly higher levels of TNF-α, IL-1, and IL-6 compared to healthy controls. Serum levels of TNF-α and IL-6 were significantly lower in PKRI and PKRI+MPA-treated animals than in placebo-treated animals, but showed no significant decrease compared to placebo-treated animals in animals treated with MPA alone. In fact, the serum levels of TNF-α and IL-6 were significantly lower in PKRI and PKRI-treated animals than in animals treated with MPA alone as well (P<0.01).
TNFα, IL-1 and IL-6 are all elevated on cancer cachexia and have all been implicated in its causation, but to different degrees (29, 30) . IL-1 is clearly involved in the induction of anorexia, through its inhibition in the CNS of the orexogenic peptide NPY (9) . TNFα is thought to decrease protein synthesis and increase protein degradation through NF-κB and the JAK/STAT pathway. Its cachectic and muscle-wasting action is facilitated in the presence of IL-1B or IL-6, but is not always seen when it is administered alone (24, 30) . Tumors are an important source of IL-6, and its action in causing cancer cachexia has been well documented. Like TNFα, its actions are also thought to be on the JAK/STAT pathway (29). MPA, in our study, had no significant effect on skeletal muscle mass, which is similar to reports for progestagens in clinical studies (17) . However, a recent study of megestrol acetate in tumor-bearing rats reported a reversal of muscle wasting (31) . Progestagens are thought to increase appetite at least in part by decreasing the synthesis and release of proinflammatory cytokines (17, 24) . However, in our study, MPA had no significant effect on serum levels of the three cytokines studied, TNFα, IL-1, and IL-6.
In conclusion, PKRI alone and combination therapy with PKRI and MPA reduce tumor growth and may alleviate cachexia.
